Aldosterone

Aldosterone is a steroid hormone classified as a mineralocorticoid, primarily produced in the adrenal cortex of the adrenal glands. Researchers primarily study aldosterone for its critical role in regulating blood pressure and fluid balance, as well as its involvement in cardiovascular and kidney diseases. Key findings indicate that excess aldosterone can lead to inflammation, fibrosis, and dysfunction in the heart and kidneys, contributing to conditions such as heart failure and chronic kidney disease. Additionally, studies suggest that aldosterone's effects may occur through both genomic and non-genomic mechanisms, complicating treatment approaches. Current research is focused on developing aldosterone synthase inhibitors and mineralocorticoid receptor antagonists to mitigate the hormone's adverse effects, highlighting its significant clinical relevance in managing cardiorenal health.

Aldosterone, also known as electrocortin, is an endogenous steroid hormone produced in the zona glomerulosa of the adrenal cortex. It belongs to the class of mineralocorticoids, which are a subset of corticosteroids. Aldosterone plays a crucial role in maintaining blood pressure and electrolyte balance by regulating sodium and potassium levels in the kidneys. Researchers have extensively studied its involvement in cardiovascular and renal diseases, particularly its contribution to inflammation, fibrosis, and dysfunction in the heart and kidneys. Aldosterone acts primarily through the mineralocorticoid receptor (MR), influencing both genomic and non-genomic pathways. The genomic action involves modulation of gene expression, while non-genomic effects are rapid and involve signaling pathways independent of gene transcription. Pharmacokinetically, aldosterone has a short circulating half-life, and its metabolism involves conversion to inactive metabolites in the liver. It is not typically administered as a therapeutic agent due to its endogenous nature. Clinically, the focus is on modulating its effects using MR antagonists or aldosterone synthase inhibitors in conditions like heart failure and chronic kidney disease. These interventions aim to mitigate the adverse effects of aldosterone excess, such as hypertension and cardiac remodeling. Regulatory approaches focus on the use of these antagonists rather than aldosterone itself, given its endogenous production and role in physiological processes.

Aldosterone acts on the mineralocorticoid receptor (MR), triggering a cascade that influences sodium and potassium balance in the kidneys. This activation leads to increased sodium reabsorption and potassium excretion, contributing to blood pressure regulation and fluid homeostasis. Additionally, aldosterone affects non-epithelial MRs in the heart, promoting fibrosis and hypertrophy through both genomic and non-genomic pathways.

Aldosterone primarily acts through the mineralocorticoid receptor (MR), activating genomic signaling pathways that lead to increased sodium reabsorption and potassium excretion in the kidneys, thereby regulating blood pressure and fluid balance. Additionally, aldosterone exerts nongenomic effects via MR-independent mechanisms, contributing to inflammation, fibrosis, and oxidative stress in cardiac and renal tissues, potentially through the activation of NADPH oxidase 2 (NOX2) and the generation of reactive oxygen species (ROS). The full spectrum of aldosterone's actions, particularly its nongenomic pathways, remains incompletely understood.

Current evidence is limited regarding the long-term effects and safety of aldosterone synthase inhibitors (ASIs) in diverse populations, particularly in patients with treatment-resistant hypertension and heart failure. Further research is needed to clarify the mechanisms underlying aldosterone's nongenomic effects, especially its impact on cardiac mitochondria and the role of oxidative stress in these processes. Additionally, larger randomized controlled trials are necessary to establish the clinical significance of aldosterone breakthrough phenomena and the optimal combination therapies involving mineralocorticoid receptor antagonists and ASIs.